NRX Pharmaceuticals Statistics
Want to see NRXP full AI Analyst Report?
NRX Pharmaceuticals (NRXP) Stock Statistics & Valuation Metrics
Total Valuation
NRX Pharmaceuticals has a market cap or net worth of $103.01M. The enterprise value is $128.55M.
- Market Cap
- $103.01M
- Enterprise Value
- $128.55M
Share Statistics
NRX Pharmaceuticals has 43,646,190 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 43,646,190
- Owned by Insiders
- 3.48%
- Owned by Institutions
- 12.24%
Financial Efficiency
NRX Pharmaceuticals’s return on equity (ROE) is 1.80 and return on invested capital (ROIC) is 106.00%.
- Return on Equity (ROE)
- 1.80
- Return on Assets (ROA)
- -2.21
- Return on Invested Capital (ROIC)
- 106.00%
- Return on Capital Employed (ROCE)
- 1.04
- Revenue Per Employee
- 42.24K
- Profits Per Employee
- -986.97K
- Employee Count
- 29
- Asset Turnover
- 0.09
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of NRX Pharmaceuticals is -3.28. NRX Pharmaceuticals’s PEG ratio is -0.03.
- PE Ratio
- -3.28
- PS Ratio
- 31.13
- PB Ratio
- -540.38
- Price to FCF
- -5.11
- Price to Operating Cash Flow
- -4.65
- PEG Ratio
- -0.03
Income Statement
In the last 12 months, NRX Pharmaceuticals had revenue of 1.23M and earned -28.62M in profits. Earnings per share was -1.34.
- Revenue
- 1.23M
- Gross Profit
- 720.00K
- Operating Income
- -16.22M
- Pretax Income
- -28.62M
- Net Income
- -28.62M
- EBITDA
- -27.81M
- Earnings Per Share (EPS)
- -1.34
Cash Flow
In the last 12 months, operating cash flow was -19.77M and capital expenditures -897,000, giving a free cash flow of -20.67M billion.
- Operating Cash Flow
- -19.77M
- Free Cash Flow
- -20.67M
- Free Cash Flow per Share
- -0.55
Dividends & Yields
NRX Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -19.57%
- Earnings Yield
- -25.56%
Stock Price Statistics
- Beta
- 0.98
- 52-Week Price Change
- -2.01%
- 50-Day Moving Average
- 2.93
- 200-Day Moving Average
- 2.98
- Relative Strength Index (RSI)
- 44.56
- Average Volume (3m)
- 1.02M
Important Dates
NRX Pharmaceuticals upcoming earnings date is Nov 16, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 17, 2026
- Next Earnings Date
- Nov 16, 2026
- Ex-Dividend Date
- ―
Financial Position
NRX Pharmaceuticals as a current ratio of 0.31, with Debt / Equity ratio of -3.96%
- Current Ratio
- 0.31
- Quick Ratio
- 0.31
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.26
- Interest Coverage Ratio
- -24.18
Taxes
In the past 12 months, NRX Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
NRX Pharmaceuticals EV to EBITDA ratio is -3.67, with an EV/FCF ratio of -3.88.
- EV to Sales
- 23.63
- EV to EBITDA
- -3.67
- EV to Free Cash Flow
- -3.88
- EV to Operating Cash Flow
- -4.06
Balance Sheet
NRX Pharmaceuticals has $26.69M in cash and marketable securities with $1.25M in debt, giving a net cash position of $25.44M billion.
- Cash & Marketable Securities
- $26.69M
- Total Debt
- $1.25M
- Net Cash
- $25.44M
- Net Cash Per Share
- $0.58
- Tangible Book Value Per Share
- -$0.07
Margins
Gross margin is 32.68%, with operating margin of -588.24%, and net profit margin of -691.81%.
- Gross Margin
- 32.68%
- Operating Margin
- -588.24%
- Pretax Margin
- -691.81%
- Net Profit Margin
- -691.81%
- EBITDA Margin
- -643.93%
- EBIT Margin
- -658.10%
Analyst Forecast
The average price target for NRX Pharmaceuticals is $36.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $36.00
- Price Target Upside
- 1375.41% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 3
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 67.07%
Scores
- Smart Score
- 6
- AI Score
- 48
